Q4 Top Performers: Labcorp (NYSE:LH) and Other Leading Testing & Diagnostics Services Stocks

Q4 Review: Testing & Diagnostics Services Stocks Performance

As the earnings season concludes, it's a great opportunity to reflect on which companies in the testing and diagnostics services sector excelled and which faced challenges. Here’s an overview of how these stocks performed in the fourth quarter, beginning with Labcorp (NYSE:LH).

Industry Overview

The testing and diagnostics sector is fundamental to healthcare, enabling early disease detection, ongoing monitoring, and prevention for hospitals, clinics, and individuals. This industry enjoys steady demand, fueled by an aging demographic, rising rates of chronic illnesses, and a growing focus on preventive care. Revenue is consistently generated through routine lab work, diagnostic imaging, and screenings, with payments coming from government programs, private insurers, and patients themselves. However, companies in this space must navigate obstacles such as pricing pressures, regulatory demands, and the constant need to invest in new technologies. Looking forward, the industry is set to benefit from trends like personalized medicine, the rise of at-home and rapid testing, and the integration of AI to improve diagnostic accuracy and efficiency. Nonetheless, uncertainties around reimbursement, competition from decentralized testing, and increased regulatory oversight could pose risks to profitability. Embracing automation and adapting to new healthcare delivery models will be crucial for continued growth and operational success.

Q4 Financial Highlights

• The five major testing and diagnostics companies we track collectively surpassed analyst revenue expectations by 2.1% in Q4.
• Despite these positive results, share prices for these companies have struggled, with an average decline of 10.7% since their latest earnings announcements.

Labcorp (NYSE:LH): Q4 Underperformance

Labcorp, a global leader performing over 600 million tests annually and participating in 90% of FDA-approved drugs in 2023, delivers laboratory and drug development services to healthcare providers and pharmaceutical companies worldwide.

For the quarter, Labcorp posted $3.52 billion in revenue, marking a 5.6% year-over-year increase. However, this figure was 1.4% below analyst forecasts. The quarter was mixed: while Labcorp exceeded full-year EPS guidance, it fell slightly short on revenue targets.

Adam Schechter, Labcorp’s Chairman and CEO, commented, “In 2025, Labcorp achieved over 7% revenue growth, double-digit adjusted EPS gains, margin improvement, and robust free cash flow, driven by ongoing strength in our Diagnostics and Central Laboratory divisions.”

Labcorp raised its full-year guidance more than any peer but also missed analyst estimates by the widest margin. The market reacted negatively, with shares dropping 14.2% since the report, now trading at $264.15.

RadNet (NASDAQ:RDNT): Q4 Standout

RadNet operates a network of over 350 imaging centers in seven states and is expanding its artificial intelligence capabilities. The company offers a range of outpatient diagnostic imaging services, including MRI, CT, PET, mammography, and X-ray scans.

In Q4, RadNet generated $547.7 million in revenue, a 14.8% increase year-over-year and 5.8% above analyst expectations. The company not only beat revenue estimates but also exceeded EPS forecasts, making it the top performer among its peers this quarter.

Despite these strong results, RadNet’s stock has declined 14.2% since the earnings release and is currently priced at $59.89.

Guardant Health (NASDAQ:GH): Rapid Growth, Mixed Outlook

Guardant Health is at the forefront of liquid biopsy technology, offering blood tests that detect cancer-related genetic mutations, enabling less invasive cancer monitoring and treatment planning.

The company reported $281.3 million in revenue for Q4, up 39.4% year-over-year and 3.5% above analyst projections. While Guardant delivered the fastest revenue growth, its full-year guidance update was the weakest among its peers. Shares have fallen 14.7% since the earnings announcement, now trading at $90.78.

NeoGenomics (NASDAQ:NEO): Solid Quarter, Market Disappointment

NeoGenomics operates accredited laboratories in the US and UK, specializing in cancer diagnostics, genetic testing, and pathology services for oncologists and healthcare providers.

For Q4, NeoGenomics reported $190.2 million in revenue, a 10.6% year-over-year increase and 1% above analyst expectations. The company also outperformed on EPS and full-year EPS guidance. Despite these achievements, the stock has dropped 16.1% since the earnings release, now trading at $9.32.

Quest Diagnostics (NYSE:DGX): Consistent Strength

Quest Diagnostics processes lab tests for roughly one-third of US adults each year, providing diagnostic services to patients, physicians, and healthcare organizations nationwide.

In Q4, Quest reported $2.81 billion in revenue, a 7.1% year-over-year rise and 1.9% above analyst estimates. The company also surpassed full-year revenue guidance and delivered a solid beat on revenue expectations. Shares have risen 3.4% since the earnings report and are now at $197.70.

Looking for Top Investment Opportunities?

If you’re interested in companies with strong fundamentals, check out our Top 6 Stocks to add to your watchlist. These businesses are well-positioned for growth, regardless of market or political shifts.

The StockStory analyst team leverages quantitative analysis and automation to deliver timely, high-quality market insights, helping investors stay ahead.